Active Ingredients: Orlistat
If patients gained weight during this period, however, a hypoenergetic diet was not initiated; rather, these patients were encouraged to maintain this higher weight.
Dietary and behavioral counseling was provided throughout the 1-y treatment period to help subjects maintain their body weights. Patients were instructed to keep a comprehensive dietary record of food and beverage intakes for 3 consecutive days at 7 time points during the 6-mo lead-in weight-loss period and at 4 time points during the 1-y treatment period.
Compliance was assessed by counting the number of capsules returned by the patients at specified clinic visits and by calculating the number of capsules that had been consumed each day.
Study design and assignment of subjects.
AE, adverse event; tid, 3 times daily. Measurements Clinic visits were scheduled weekly for the first 2 mo of the 6-mo lead-in weight-loss period and every 2 wk thereafter.
During the 1-y treatment period, subjects were seen on day 1, at 2-wk intervals during month 1, every month between months 1 and 5, and every 2 mo thereafter. Body weight was measured at every clinic visit.
Fasting serum glucose and insulin concentrations were also measured at these visits, with one additional measurement during both the 6-mo lead-in weight-loss period and the 1-y treatment period.
The pharmacodynamic effect of orlistat was assessed by measuring fecal fat content.
Fecal collections were analyzed by Medi-Lab Bioprofil, Copenhagen. Anyway, to cut a long story short, I was starting to get a bit cocky on the brakes and had ended up on the grass a couple of times with the result that I failed to qualify for the final.
We still got a race anyway and it was during this that disaster struck. I got away from the start about mid pack and started to work my way up.